• 1H FY26 unaudited revenue of $47.9m, delivering underlying EBITDA of $1.1m
• Cashflow from operations adversely impacted by $0.8m payment for due diligence costs
• Maintained robust balance sheet with $7.5m cash, $7.7m inventory, and $6m in unutilised debt facilities

SciDev Limited reported 1H FY26 unaudited revenue of $47.9m, down 4% from $49.9m in 1H FY25, delivering an underlying EBITDA of $1.1m (1H FY25: $3.4m). Cashflow from operations amounted to negative $0.7m, adversely impacted by the $0.8m payment for due diligence costs related to a potential acquisition in 2H FY25 which subsequently did not progress. The company also incurred a further $0.7m in abnormal expenses related primarily to redundancies and restructuring. Despite these challenges, SciDev maintained a robust balance sheet with total cash of $7.5m, $7.7m in inventory and a further $6m in unutilised debt facilities as of 31 December 2025. The company continued to build strength across the Group, with stronger revenue from Chemical Services, a return to profitability in Water Technologies domestically, and growing a recurring revenue base to account for over half of total revenue.

The outlook for the Chemical Services segment remains positive, and SciDev anticipates growth by delivering bespoke chemistry to new clients, through direct sales and by progressing the strategic Joint Venture with Nuoer Chemicals. In the Water Technologies segment, the benefits of transitioning the international operations to a lower cost channel partner strategy are expected to reduce costs by nearly $3 million annually, while retaining access to the significant long-term potential of these markets.